Traws Pharma

Yahoo Finance • 4 months ago

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients, representing a significant population with few effective treatment options Final... Full story

Yahoo Finance • 6 months ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single-arm trial assessing sa... Full story

Yahoo Finance • 6 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 6 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheime... Full story

Yahoo Finance • 7 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety... Full story

Yahoo Finance • 8 months ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease in... Full story

Yahoo Finance • 8 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human healt... Full story

Yahoo Finance • 9 months ago

Traws Pharma announces chief financial officer transition

Traws Pharma, Inc. (NASDAQ:TRAW), a small-cap biotech company with a market capitalization of $8.12 million, announced Thursday that Nora Brennan has notified the company of her decision to resign from her role as Interim Chief Financial O... Full story

Yahoo Finance • 9 months ago

Traws Pharma advances antiviral pipeline with multiple regulatory submissions

* Traws Pharma (NASDAQ:TRAW [https://seekingalpha.com/symbol/TRAW]) on Monday announced [https://seekingalpha.com/pr/20151380-traws-pharma-advances-antiviral-pipeline-with-multiple-regulatory-submissions] multiple regulatory submissions... Full story

Yahoo Finance • 9 months ago

Traws Pharma advances clinical trials for influenza and COVID treatments

NEWTOWN, Pa. - Traws Pharma, Inc. (NASDAQ:TRAW), a small-cap pharmaceutical company currently trading at $1.43, has submitted multiple regulatory filings to advance clinical trials for its antiviral drug candidates, according to a press re... Full story

Yahoo Finance • 9 months ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path... Full story

Yahoo Finance • 10 months ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human healt... Full story

Yahoo Finance • last year

Traws Pharma Announces Management Updates

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws... Full story

Yahoo Finance • last year

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird FluRatutrelvir, a main protease inhibitor, to be used without... Full story

Yahoo Finance • last year

Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimenPreparations are underway for FDA interactions a... Full story

Yahoo Finance • last year

Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 dataFull dataset to be highlighted during Investor... Full story

Yahoo Finance • last year

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respi... Full story